The ubiquitin ligase RNF181 stabilizes ERα and modulates breast cancer progression.

ABSTRACT: ERα positive breast cancer accounts for 70% of breast malignancies. Compared with ERα negative types, ERα positive breast cancer could be effective controlled by endocrine therapy. However, more than half of the patients will develop endocrine resistance, making it an important clinical issue for breast cancer therapy. Endocrine resistance might be caused by multiple alternations, including the components of ERα signaling, during tumor progression. Thus, it is urgent and necessary to uncover the molecular mechanisms that controls ERα expression and stability to improve breast cancer therapeutics. In our current study, we identifies that the ubiquitin ligase RNF181 stabilizes ERα and facilitates breast cancer progression. The expression of RNF181 is correlated with ERα level in human breast

SUBMITTER: Zhu J 

PROVIDER: S-EPMC7605433 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature